Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOTERIA: Long-term Follow-up Study of Sotatercept in PAH
NCT07218029Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2021
- Primary completion
- Dec 2028
- Countries
- 27
01
Overview
A Phase 3 trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co.. Started May 2021; status: active, not recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07218029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218029.